Drug targeting: is race enough?
Meredith
M
Wadman
D001741:Black or African American / Q000208:ethnology* / Q000235:genetics; D044466:Asian People / Q000208:ethnology / Q000235:genetics; D004338:Drug Combinations; D004345:Drug Industry; D066246:ErbB Receptors / Q000235:genetics; D000077156:Gefitinib; D006333:Heart Failure / Q000188:drug therapy* / Q000208:ethnology* / Q000235:genetics; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage* / Q000627:therapeutic use*; D007548:Isosorbide Dinitrate / Q000008:administration & dosage* / Q000627:therapeutic use*; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D004338:Drug Combinations; D011799:Quinazolines; C431665:isosorbide-hydralazine combination; D006830:Hydralazine; D066246:ErbB Receptors; D007548:Isosorbide Dinitrate; D000077156:Gefitinib